Proactive Investors - Run By Investors For Investors

ANGLE on track to complete key Parsortix study in current quarter

ANGLE is looking to become the first company to receive FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis
parsortix
Parsortix analyses blood for signs of cancer

ANGLE PLC (LON:AGL) expects to complete the clinical study of its Parsortix cancer detection technology by the end of March this year.

So far, 369 of the required 400 patients – 200 with breast cancer and 200 healthy – have been enrolled in the study.

READ: ANGLE device has lymph node potential, says German research team

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the “continued progress” to date, ANGLE remains confident in wrapping up the trial and data analysis in the current quarter.

“The first half of the year has been one of continued progress by ANGLE and we look forward to completing our FDA clinical and analytical studies in metastatic breast cancer in the US in Q1 2019 with only 31 more subjects to recruit,” said chairman Garth Selvey.

Ovarian cancer test progressing well

In the same update, the AIM company confirmed that the pre-study of an ovarian cancer test, which combines Parsortix with its HyCEAD Ziplex analysis platform, is due to start in the current quarter, subject to ethics approval.

“Significant progress has also been achieved in the optimisation of our recently acquired HyCEAD Ziplex platform for downstream analysis in preparation for our ovarian cancer clinical verification study,” added chairman Selvey.

Healthy cash balance

In the six months ended 31 October, revenue and grant income totalled £0.4mln (H1 17/18: £0.2mln).

Loss from continuing operations widened to £4.2mln (H1 17/18: £3.4mln) reflecting planned investment.

Following a £12.7mln fundraise back in June, ANGLE ended the half with £14.9mln in the bank (April 2018: £7.6mln).

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use